Abstract

To examine empagliflozin potential for treating acute decompensated heart failure. 108 acute decompensated heart failure patients who were treated in our hospital from January 2022 to January 2023 were randomly split into two groups, each with 54 patients as research group and the control group. The research group supplemented the control group with empagliflozin, while the control group continued to receive traditional anti-acute decompensated heart failure therapy. Comparisons were made between the two groups clinical effectiveness, cardiac and renal function markers, health status, and follow-up outcomes. The research group’s total treatment effectiveness was better than the control group’s (p<0.05). Following treatment, the research group had lower left ventricular end-systolic volume, left ventricular end-diastolic volume, serum creatinine, and blood urea nitrogen than the control group (p<0.05); the research group also had lower left ventricular ejection fraction, glomerular filtration rate, and the Kansas city cardiomyopathy questionnaire. Between the two groups, there was no discernible difference in the rate of decline (p>0.05). The research group outperformed the control group in terms of mortality and the risk of re-hospitalization within 60 d (p<0.05). Engramine is a highly valuable therapy option for acute decompensated heart failure since it is efficient, can enhance cardiac function, reduce renal impairment, and improve patient health.